US12594055B1 probe apparatus, Big Ridge Solutions, 7th Apr

US12594055B1 probe apparatus, Big Ridge Solutions, 7th Apr

Injectable off-the-shelf cartilage, tendon, and ligament repair compositions and methods of use

The USPTO granted Patent US12595463B2 to EPIBONE, INC. covering injectable compositions comprising condensed mesenchymal cell bodies and hydrogels for cartilage, tendon, and ligament repair. The patent includes 11 claims and covers methods of treating connective tissue defects and cartilage injuries using cell-based therapies.

Integrated system for 3D tissue culture

The USPTO granted Patent US12595449B2 to VALO Health, Inc. covering an integrated system with embedded electrodes for growing, maintaining, and using 3D tissues in vitro. The patent includes 13 claims under CPC classifications C12M and C12N covering scalable, automated tissue stimulation devices and systems. The filing date was February 3, 2021, with Application No. 17798048.

Corynebacterium Microorganism with Enhanced L-Arginine Productivity and Production Method

USPTO granted patent US12595461B2 to DAESANG CORPORATION for a Corynebacterium mutant strain with enhanced L-arginine or L-citrulline productivity. The strain has enhanced activity of acetylglutamate kinase involved in the L-arginine biosynthesis pathway. Inventors are Mi Ryu, Sun Jun Yoon, In Pyo Hong, and Seok Hyun Park. The patent covers 3 claims.

Engineered immune cells with micro-clusters

USPTO granted patent US12595291B2 to A2 Biotherapeutics, Inc. covering engineered immune cells comprising activating and blocking receptors that form micro-clusters upon contacting target or non-target cells. The patent contains 16 claims and names Alexander Kamb as inventor, with the application originally filed on September 21, 2021.

ETH Zurich CRISPR Transcriptional Recording Patent B2

The USPTO granted patent US12595468B2 to ETH Zurich for a method of recording a cell's transcriptome using CRISPR spacer acquisition from RNA. The invention involves a reverse transcriptase-Cas1 fusion protein and Cas2 polypeptide under inducible promoter control, enabling temporal recording of gene expression patterns. The patent lists Randall Jeffrey Platt and Florian Schmidt as inventors and contains 8 claims.

Engineered Nucleases Targeting Factor VIII Genes for Hemophilia A Treatment

The USPTO granted Patent US12595470B2 to Precision BioSciences, Inc. covering engineered nucleases that recognize and cleave a recognition sequence within the int22h-1 sequence of the Factor VIII gene. The patent also covers methods of using such nucleases to create genetically-modified cells and their use in pharmaceutical compositions for treating hemophilia A. The patent contains 18 claims and names five inventors.

Methods and systems for extracting nucleic acids from a biological sample

The USPTO granted patent US12595475B2 to Kryptos Biotechnologies, Inc. on April 7, 2026, covering methods and systems for extracting nucleic acids from biological samples using solid-phase substrate binding and magnetic field trapping at a chamber site. The patent includes 11 claims for an automated purification process involving wash buffer, immiscible fluid, and elution buffer steps.

Genetically modified Bacillus subtilis strain for D-psicose 3-epimerase production

USPTO granted patent US12595473B2 to ROQUETTE FRERES for a genetically modified Bacillus subtilis strain transformed with an optimized vector for producing D-psicose 3-epimerase. The patent covers the bacterial strain, vectors, and methods of using the strain for enzyme production. The grant date is April 7, 2026, with 4 claims.

Mannanase variants and polynucleotides encoding same

USPTO granted patent US12595472B2 to BASF SE for mannanase enzyme variants at least 75% identical to SEQ ID NO: 2 or 3, including encoding polynucleotides, expression constructs, and host cells. The patent, filed February 12, 2021, contains 14 claims and is classified under CPC C12N 9/2488.